Introduction

Chronic hepatitis C virus (HCV) infection is prevalent worldwide, with approximately 170 million persons suffering from this disease [1,2]. The epidemiology, natural history of chronic infection, virology and medical therapy for HCV infection has been well documented [2]. However, pandemic HCV infection remains a serious problem of global concern because of other long-term consequences of the infection. Patients with HCV infection may progress to cirrhosis and subsequently develop complications such as ascites, varical bleeding, encephalopathy and hepatocellular carcinoma [1,2].

Stroke is the second leading cause of death worldwide and the leading cause of acquired disability in adults in most regions [3–5]. An international multicentre population-based study has identified cardiac diseases, hypertension, diabetes, smoking, alcohol intake, unhealthy diet, abdominal obesity, lack of exercise, psychosocial stress and depression as risk factors associated with 90% of stroke risk [5]. Nevertheless, other risk factors associated with the prevalence of stroke require further study.

Substantial experimental and epidemiologic evidence has documented the potential role of HCV infection in the development and progression of carotid atherosclerosis [6–9]. Altered cerebral metabolism in patients with chronic HCV infection has been proposed [10], yet the association of stroke with HCV infection as a consequence of carotid atherosclerosis remains unclear. Although chronic HCV infection is considered an independent risk predictor of cerebrovascular mortality, whether HCV infection increases the incidental event of stroke is undetermined [11]. To clarify the potential impact of HCV infection on stroke, we conducted a population-based cohort study using reimbursement claims from Taiwan’s National Health Insurance Research Database with a follow-up period of 4 to 7 years.

Methods

Study design and sample

Taiwan’s National Health Insurance has documented all medical claims for insured beneficiaries since 1996. With identification numbers scrambled to protect patient privacy,
information collected for this study included gender, birthday, disease codes, health care rendered, medications prescribed, admissions, discharges, medical institutions and physicians providing services. In this longitudinal cohort study with a randomly selected population of one million insured subjects, we identified patients aged 20 years and older who were newly diagnosed with HCV infection in 2002–2004 as the HCV cohort. The non-HCV cohort comprised people aged ≥20 years randomly selected from individuals without HCV infection at a ratio of 1:4 (exposed vs. non-exposed), with frequency matching by age and sex during the same time period. Patients with previous history of stroke were excluded when establishing both cohorts. Overall, 20,470 insured adults were included for the prospective analysis. This follow-up started in 2002 to include all incident stroke cases or until censoring due to death, loss to follow-up or other causes by the end of 2008 to explore whether the HCV cohort had increased risk of developing stroke.

Criteria and definition

The International Code of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) was used to identify parameters from individual health reimbursement claims. The HCV cohort consisted of patients with diagnosis of HCV infection (ICD-9-CM 070.41, 070.44, 070.51 and 070.54), and the non-HCV cohort was controls with no diagnosis of HCV infection. Both groups were treated as fixed cohorts. HCV cohort was defined as patients with primary diagnosis according to positive serum results during hospitalization or outpatient visits. New stroke cases (ICD-9-CM of 430–438) were further defined from emergency and inpatient medical records afterwards. Co-existing medical conditions such as obesity (ICD-9-CM 278), hyperlipidemia (ICD-9-CM 272.9), diabetes (ICD-9-CM 250), ischemic heart disease (ICD-9-CM 410–414) and hypertension (ICD-9-CM 401, 402, 403, 404 and 405) were considered as covariates in this study. We further considered associated alcohol-related illnesses as alcoholic psychoses (ICD-9-CM 291), alcohol dependence syndrome (ICD-9-CM 303), alcohol abuse (ICD-9-CM 305), alcoholic fatty liver (ICD-9-CM 571.0), acute alcoholic hepatitis (ICD-9-CM 571.1), alcoholic cirrhosis of liver (ICD-9-CM 571.2) and alcoholic liver damage (ICD-9-CM 571.3). In addition, subjects with history of cessation of cigarette smoking were also identified. Medication use of statins and angiotensin-converting enzyme (ACE) inhibitor during the follow-up period were also considered in this study [12,13]. The National Health Insurance Research Database has been verified as a valid resource for population-based research [14].

Statistical analysis

We compared the distribution of demographic factors and the proportions of comorbidities between the HCV and non-HCV cohorts. The crude incidence rates of stroke were calculated in the follow-up period until the end of 2008. The duration of observation for each beneficiary was calculated until stroke was diagnosed or the beneficiary was censored for death, migration or discontinuation of insurance coverage. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for HCV infection and other factors associated with stroke risk were calculated using Cox proportional hazard analyses. Two-sided probability values less than 0.05 were considered statistically significant. We considered associated factors in the univariate regressions with a p<0.2 in the multivariate Cox proportional hazard model to estimate the hazard ratios (HRs) for stroke. All analyses were performed by SAS software version 9.1 (SAS Institute Inc., Carey, NC, USA).

Ethical Approval

Insurance reimbursement claims used in this study were from Taiwan’s National Health Insurance Research Database, which is available for public access. This study was conducted in accordance with the Helsinki Declaration. To protect personal privacy, the electronic database was decoded with patient identifications scrambled for further public access for research. According to National Health Research Institute regulations, informed consent is not required due to decoded and scrambled patient identification. However, this study was evaluated and approved by Taiwan’s National Health Research Institutes.

Results

The eligible study subjects were 4094 persons in the HCV cohort and 16,376 persons in the non-HCV cohort (Table 1). The HCV infection cohort had a higher proportion of individuals with low incomes, living in less urbanized areas, and visiting the smoking cessation clinic compared with individuals without HCV infection. Patients with HCV infection were also more likely to have hypertension (42.4% vs. 34.9%, p<0.0001), hyperlipidemia (40.4% vs. 26.8%, p<0.0001), diabetes mellitus (25.6% vs. 15.9%, p<0.0001), ischemic heart disease (21.7% vs. 15.0%, p<0.0001), alcohol-related disease (10.3% vs. 1.5%, p<0.0001) and obesity (1.8% vs. 1.1%, p=0.0003). There were significant differences in medication use, with use of stains (p=0.0102) and ACE inhibitor (p<0.0001) higher in the HCV group than in the non-HCV group.

Table 2 shows that the incidence of stroke was significantly higher in the HCV cohort than in the non-HCV cohort (25.3 vs. 19.3 per 1000 person-years) with an unadjusted HR of 1.30 (95% CI 1.17 to 1.44). Female gender, greater age, lower income, living in less urbanized areas, hyperlipidemia, diabetes, heart disease and hypertension were also associated with the risk of stroke before adjustment. The unadjusted HRs of risk of stroke for users of statins and ACE inhibitor were 1.32 (95% CI 1.17 to 1.49) and 2.02 (95% CI 1.85 to 2.21), respectively. Those who received smoking prevention services seemed to benefit from a decreased risk of stroke.

After adjustment, HCV infection demonstrated a HR of 1.38 (95% CI 1.24 to 1.53) for stroke, or of 1.27 (95% CI 1.14 to 1.41) in the multivariate model (Table 3). Age (HR 1.68, 95% CI 1.62 to 1.74), low income (HR 1.47, 95% CI 1.14 to 1.90), history of diabetes (HR 1.23, 95% CI 1.11 to 1.36), ischemic heart disease (HR 1.17, 95% CI 1.06 to 1.30) and hypertension (HR 1.48, 95% CI 1.06 to 1.30) were also significant and independent factors associated with increased risk of stroke. After adjustment, the use of statins (HR 0.79, 95% CI 0.69 to 0.90) and ACE inhibitor (HR 0.75, 95% CI 0.67 to 0.83) were associated with reduced risk of stroke.

Discussion

In this population-based cohort study, we found that chronic HCV infection was associated with significantly increased risk of stroke after controlling for conventional stroke risk factors. This further upgrades previous associated findings that chronic HCV infection might be linked with carotid atherosclerosis [6–9,15,16] and acute myocardial infarction [17]. To the best of our knowledge, our study is the first to investigate the relationship between HCV infection and stroke event in a population-based longitudinal cohort.

Previous studies have reported positive relationships between HCV infection and carotid intima-media thickness, plaque and
stroke. The association varied in populations with different prevalence of HCV infection, risk factors and study design [6–9,18–21]. A cross-sectional study supported the possible link between HCV infection and carotid atherosclerosis in subjects without severe liver dysfunction [20]. A prospective population-based study also suggested that chronic infection plays an important role in human carotid atherogenesis [22]. Positive correlations between HCV infection, carotid atherosclerosis and cardiovascular diseases also have been investigated in specific patient populations. Among patients with type 2 diabetes, significant association between HCV infection and ultrasonographic-evident carotid atherosclerosis was noted [7]. HCV infection is also closely associated with increased aortic stiffness and cardiovascular events in dialysis patients [22]. In addition, HIV-infected individuals with HCV co-infection were found to have increased risk of cardiovascular disease and acute myocardial infarction [18,19]. Aslam’s research review concluded that HCV-positive subjects had higher incidence of carotid atherosclerotic plaques compared to HCV-negative individuals [9].

### Table 1. Comparisons in demographic characteristics and comorbidities between cohorts with and without hepatitis C infection.

| Infection with hepatitis C | No (N = 16,376) | Yes (N = 4094) | p-value |
|----------------------------|----------------|---------------|---------|
| Sex                        | n (%)          | n (%)         | 1.00    |
| Female                     | 8184 (50.0)    | 2046 (50.0)   |         |
| Male                       | 8192 (50.0)    | 2048 (50.0)   |         |
| Age, years                 |                |               | 1.00    |
| 20–29                      | 1200 (7.3)     | 300 (7.3)     |         |
| 30–39                      | 2068 (12.6)    | 517 (12.6)    |         |
| 40–49                      | 3384 (20.7)    | 846 (20.7)    |         |
| 50–59                      | 3916 (23.9)    | 979 (23.9)    |         |
| 60–69                      | 3392 (20.7)    | 848 (20.7)    |         |
| ≥70                        | 2416 (14.8)    | 604 (14.8)    |         |
| Low-income                 | 289 (1.8)      | 98 (2.4)      | 0.0082  |
| Urbanization               | <0.0001        |               |         |
| Low                        | 4014 (24.5)    | 1329 (32.5)   |         |
| Moderate                   | 4055 (24.8)    | 1041 (25.4)   |         |
| High                       | 3980 (24.3)    | 951 (23.2)    |         |
| Very high                  | 4327 (26.4)    | 773 (18.9)    |         |
| Smoking cessation service  | 315 (1.9)      | 133 (3.3)     | <0.0001 |
| History of disease         |                |               |         |
| Hypertension               | 5718 (34.9)    | 1736 (42.4)   | <0.0001 |
| Hyperlipidemia             | 4396 (26.8)    | 1655 (40.4)   | <0.0001 |
| Diabetes                   | 2274 (13.9)    | 1047 (25.6)   | <0.0001 |
| Congestive heart disease   | 2451 (15.0)    | 888 (21.7)  | <0.0001 |
| Alcohol-related disease    | 252 (1.5)      | 421 (10.3)   | <0.0001 |
| Obesity                    | 184 (1.1)      | 75 (1.8)     | 0.0003  |
| Statin use                 | 2112 (12.9)    | 467 (11.4)   | 0.0102  |
| ACE inhibitor use          | 4049 (24.7)    | 1390 (31.5)  | <0.0001 |

ACE, angiotensin-converting enzyme. doi:10.1371/journal.pone.0031527.t001

### Table 2. Incidences of stroke and Cox model measured hazard ratios of stroke associated with hepatitis C infection, demographic factors and comorbidities.

|                | Person-years | Cases | Incidence ratea | HR (95% CI) |
|----------------|--------------|-------|-----------------|-------------|
| Univariate     |              |       |                 |             |
| Hepatitis C    |              |       |                 |             |
| No             | 77686        | 1499  | 19.3            | 1.00 (reference) |
| Yes            | 19066        | 482   | 25.3            | 1.30 (1.17–1.44) |
| Sex            |              |       |                 |             |
| Female         | 48830        | 1069  | 21.9            | 1.00 (reference) |
| Male           | 47922        | 912   | 19.0            | 0.87 (0.80–0.95) |
| Age, years     |              |       |                 |             |
| 20–29          | 7413         | 11    | 1.5             | 1.00 (reference) |
| 30–39          | 12806        | 44    | 3.4             | 2.31 (1.19–4.48) |
| 40–49          | 20804        | 160   | 7.7             | 5.17 (2.81–9.53) |
| 50–59          | 23637        | 414   | 17.5            | 11.8 (6.48–21.5) |
| 60–69          | 19690        | 645   | 32.8            | 22.1 (12.2–40.1) |
| ≥70            | 12403        | 707   | 57.0            | 38.5 (21.2–69.9) |
| Low-income     | 1689         | 60    | 35.5            | 1.75 (1.36–2.27) |
| Urbanization   | <0.0001      |       |                 |             |
| Low            | 24636        | 686   | 27.8            | 1.58 (1.40–1.79) |
| Moderate       | 24258        | 468   | 19.3            | 1.10 (0.96–1.25) |
| High           | 23530        | 400   | 17.0            | 0.97 (0.85–1.11) |
| Very high      | 24328        | 427   | 17.6            | 1.00 (reference) |
| Smoking cessation service | 2256 | 23  | 10.2           | 0.49 (0.33–0.74) |
| Alcohol-related illness | 3042 | 69  | 22.7           | 1.10 (0.87–1.40) |
| Obesity        | 1276         | 24    | 18.8            | 0.92 (0.61–1.37) |
| History of hyperlipidemia | 29059 | 749 | 25.8         | 1.41 (1.29–1.55) |
| History of diabetes | 15162 | 576 | 38.0         | 2.20 (2.00–2.42) |
| History of heart disease | 15029 | 641 | 42.7          | 2.60 (2.36–2.85) |
| History of hypertension | 34095 | 1270 | 37.2       | 3.28 (2.99–3.59) |
| Statin use     | 12644        | 328   | 25.9            | 1.32 (1.17–1.49) |
| ACE inhibitor use | 25010 | 820  | 32.8           | 2.02 (1.85–2.21) |

*Cox proportional hazards regression model. Estimates for the person-years are calculated based on the number of the participant with a follow-up of 1000 person-years. ACE, angiotensin-converting enzyme; CI, confidence interval; HR, hazard ratio. doi:10.1371/journal.pone.0031527.t002

Chronic HCV infection per se could be considered a chronic inflammatory process that might play a role in the pathogenesis of carotid arterial remodelling [7]. Localization of RNA of HCV in human carotid plaques provides strong evidence for an association between HCV infection and atherosclerosis [6]. Forton et al. hypothesized that HCV infection might be related to cerebral dysfunction, particularly neuropsychological symptoms and cognitive impairment [23]. Furthermore, chronic HCV infection has potential effects on cerebral metabolism which could not be explained by hepatic encephalopathy or a drug-induced insult [10]. However, further large-scale prospective studies are needed to investigate these findings and hypotheses.

Controversy persists about correlation between HCV infection and carotid atherosclerosis or cardiovascular disease [15–17]. A
That chronic HCV infection is an independent risk predictor of cerebrovascular deaths, showing a severity-dependent cerebrovascular mortality with increasing serum HCV RNA level [11]. However, that study was limited by non-validated data derived from the diagnosis on death certificate addressed by administrative instead of medical personnel [11]. The previous study also did not consider the effects of cardiovascular medication use on risk of stroke [12,13]. As a population cohort, our findings suggest a positive association between chronic HCV infection and stroke event which was identified from National Health Insurance records after the adjustment for sociodemographic factors, history of diseases and cardiovascular medication use. Our study is the first to report the association of HCV infection and increased risk of stroke [14].

Our study differs from previous research on HCV infection and stroke in several aspects. Retrospective exclusion of individuals with previous medical history of stroke helps us define fresh cases and clarify the correlation between HCV infection and development of stroke. In addition, considering the major cardiovascular risk factors for the data analysis, we could examine the effects of HCV infection independently on stroke with risk confounders. Several studies have positively linked HCV infection with type 2 diabetes and metabolic syndrome, which are important risk factors for stroke [23–26]. Even though type 2 diabetes and hypertension may increase the risk of stroke, this study demonstrated an independent risk of stroke after controlling for diabetes and hypertension in multivariable analyses. These results further suggest HCV infection plays an independent and unique role in incident stroke.

Our study has several limitations. Sub-clinical HCV-infected patients might be included among our non-HCV cohort. The history of hypertension, diabetes, hyperlipidemia, ischemic heart disease, alcohol-related diseases and obesity was based on medical claims in this study and might be underestimated. Moreover, our study has no data for patient lifestyle associated with stroke. This study mainly focused on clinical end points as detailed by medical reimbursement claims, rather than on underlying pathologic lesions in vessels. In addition, this study could not provide a disease severity-dependent relationship between HCV infection and stroke. We postulate that there might be a dose-response (time-dependent) relationship between serum HCV RNA levels and risk of stroke event [11].

In conclusion, we identified an independent association between chronic HCV infection and risk of stroke after controlling for traditional stroke risk factors with a population-based longitudinal cohort. Our data suggest a need for regular screening for cardiovascular risk factors and preclinical atherosclerosis among patients with HCV infection for early prevention of atherosclerotic disease and stroke.

**Author Contributions**

Conceived and designed the experiments: CCL TLC. Performed the experiments: CCL TCS FCS WHC TLC. Analyzed the data: CCL TCS. Contributed reagents/materials/analysis tools: TCS FCS WHC TLC. Wrote the paper: CCL.
10. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, et al. (2001) Evidence for a cerebral effect of the hepatitis C virus. Lancet 358: 38–39.

11. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, et al. (2010) Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 41: 2894–2900.

12. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. (2011) Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoeconomics Drug Saf 20: 236–242.

13. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, et al. (2009) Carotid and femoral atherosclerosis in chronic hepatitis C: a 5-year follow-up. Angiology 59: 717–720.

14. Volzke H, Schwahn C, Wolf B, Menzel R, Robinson DM, et al. (2004) Hepatitis B and C virus infections and the risk of atherosclerosis in a general population. Atherosclerosis 174: 99–103.

15. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. (2006) No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 43: e53–e56.

16. Freiberg MS, Cheng DM, Kraemer KL, Saiz R, Kuller LH, et al. (2007) The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals. AIDS 21: 193–197.

17. Bedimo R, Westfall AO, Magavero M, Drezekr H, Khanna N, et al. (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 11: 462–468.

18. Ishizaka Y, Ishihara N, Takahashi E, Unuma T, Tooda E, et al. (2003) Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 67: 26–30.

19. Oyake N, Shimada T, Murakami Y, Ishibashi Y, Satoh H, et al. (2008) Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol 21: 345–353.

20. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, et al. (2003) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103: 1064–1070.

21. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, et al. (2003) Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98: 2064–2071.

22. White DL, Raitzou V, El-Serag HB (2008) Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 49: 831–844.

23. Sheikh MY, Choi J, Quadri I, Friedman JE, Sanyal AJ (2008) Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 47: 2127–2133.

24. Rouabhia S, Malek R, Bouneker H, Dekken A, Bendali Amor F, et al. (2010) Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol 16: 3427–3431.

25. Biffi A, Devan VJ, Anderson CD, Costellini L, Furie KL, Rosand J, et al. (2011) Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke 42: 1314–1319.

26. Shah NR, Ogdenbe G (2010) ACP Journal Club. Review: first-line low-dose thiazides and ACE inhibitors reduce mortality and morbidity in adults with hypertension. Ann Intern Med 152: JC1–4.